Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma

American Journal of Veterinary Research

Volumn 67, Issue 1, 2006, Pages 145-151

  Selting, Kim A ^a,c   Ogilvie, Gregory K ^a,d   Gustafson, Daniel L ^b   Long, Michael E ^b   Lana, Susan E ^a   Walton, Judy A ^a   Hansen, Rodney A ^a,e   Turner, A Simon ^a   Laible, Irene ^a   Fettman, Martin J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d Angel Care Cancer Center   (United States)

^e WEBER STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DOXORUBICIN; DOXORUBICINOL; FISH OIL; OMEGA 3 FATTY ACID; SOYBEAN OIL;

ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY COMPOSITION; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID DIET; LOW FAT DIET; LYMPHOMA; NONHUMAN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY SUPPLEMENTS; DOG DISEASES; DOGS; DOXORUBICIN; FATTY ACIDS, OMEGA-3; HALF-LIFE; LYMPHOMA; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS; GLYCINE MAX; IVA;

EID: 33645214015     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.1.145     Document Type: Article

References (39)

1. Jacquet JM, Bressolle F, Galtier M, et al. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 1990;27:219-225.
2. Piscitelli SC, Rodvold KA, Rushing DA, et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993;53:555-561.
3. Preisler HD, Gessner T, Azarnia N, et al. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1984;12:125-130.
4. Bielack SS, Erttmann R, Kempf-Bielack B, et al. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996;32A:1652-1660.
5. Stallard S, Morrison JG, George WD, et al. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother Pharmacol 1990;25:286-290.
6. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988;6:1321-1327.
7. Twelves CJ, Dobbs NA, Gillies HC, et al. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 1998;42:229-234.
8. Behnia K, Boroujerdi M. Investigation of the enterohepatic recirculation of adriamycin and its metabolites by a linked-rat model. Cancer Chemother Pharmacol 1998;41:370-376.
9. Bronchud MH, Margison JM, Howell A, et al. Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1990; 25:435-439.
10. Dobbs NA, Twelves CJ, Gillies H, et al. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995;36:473-476.
11. Cusack BJ, Young SP, Loseke VL, et al. Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother Pharmacol 1992;30:145-148.
12. Maguire PJ, Fettman MJ, Smith MO, et al. Effects of diet on pharmacokinetics of phenobarbital in healthy dogs. J Am Vet Med Assoc 2000;217:847-852.
13. Ogilvie GK, Fettman MJ, Mallinckrodt CH, et al. Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Cancer 2000;88:1916-1928.
14. Guffy MM, North JA, Burns CP. Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 1984;44:1863-1866.
15. Hagve T-A, Woldseth B, Brox J, et al. Membrane fluidity and fatty acid metabolism in kidney cells from rats fed purified eicosapentaenoic acid or purified docosahexaenoic acid. Scand J Clin Lab Invest 1998;58:187-194.
16. Hardman WE, Avula CP, Fernandes G, et al. Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 2001;7:2041-2049.
17. Fettman MJ, Phillips RW. Dietary effects on drug metabolism. In: Hand MS, Thatcher CD, Remillard RL, et al, eds. Small animal clinical nutrition. 4th ed. Marceline, Mo: Walsworth Publishing Co, 2000;923-939.
18. Abulrob AN, Mason M, Bryce R, et al. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. J Drug Target 2000;8:247-256.
19. Das UN, Madhavi N, Sravan Kumar G, et al. Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukot Essent Fatty Acids 1998;58:39-54.
20. Hansen RA, Ogilvie GK, Davenport DJ, et al. Duration of effects of dietary fish oil supplementation on serum eicosapentaenoic acid and docosahexacnoic acid concentrations in dogs. Am J Vet Res 1998;59:864-868.
21. Valerius KD, Ogilvie GK, Mallinckrodt CH, et al. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997;210:512-516.
22. de Jong J, Geurand WS, Schoofs PR, et al. Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection. J Chromatogr 1991;570:209-216.
23. Gustafson DL, Rastatter JC, Colombo T, et al. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context ofa physiologic model. J Pharm Sci 2002;91:1488-1501.
24. Ratain MJ, Robert J, vander Vijgh WJF. Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991;9:871-876.
25. Rousseau A, Marquet P. Application of pharmacokinetic modeling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002;16:253-262.
26. Arrington KA, Legendre AM, Tabeling GS, et al. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 1994;55:1587-1592.
27. Waddle JR, Fine RL, Case BC, et al. Phase 1 and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs. Cancer Chemother Pharmacol 1999;44:74-80.
28. Wilke AV, Jenkins C, Milligan AJ, et al. Effect of hyperthermia on normal tissue toxicity and on adriamycin pharmacokinetics in dogs. Cancer Res 1991;51:1680-1683.
29. Tonetti M, Astroff AB, Satterfield W, et al. Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes. Am J Vet Res 1991;52:1630-1635.
30. Baldwin JR, Phillips BA, Overmyer SK, et al. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. Cancer Chemother Pharmacol 1992; 30:433-438.
31. Oosterbaan MJM, Dirks RJM, Vree TB, et al. Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. Pharm Res 1984;1:33-38.
32. Price GS, Page RL, Riviere JE, et al. Effect of whole-body hyperthermia on lonidamine and doxorubicin pharmacokinetics and toxicity in dogs. Int J Hyperthermia 1995;11:545-559.
33. Ku Y, Kusunoki N, Kitagawa T, et al. Pharmacokinetics of adriamycin and cisplatin for anhepatic chemotherapy during liver transplantation. Cancer Chemother Pharmacol 1997;40:457-462.
34. Riviere JE. Study design and data analysis. In: Riviere JE, ed. Comparative pharmacokinetics: principles, techniques and applications. Ames, Iowa: Iowa State University Press, 1999;239-259.
35. Leca F, Marchiset-Leca D, Noble A, et al. New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. Eur J Drug Metab Pharmacokinet 1991;16:107-111.
36. Gustafson DL, Long ME, Zirrolli JA, et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 2003;52:159-166.
37. Sturgill MG, August DA, Brenner DE. Hepatic enzyme induction with phenobarbital and doxorubicin metabolism and myelotoxicity in the rabbit. Cancer Invest 2000;18:197-205.
38. Hirafuji M, Machida T, Hamaue N, et al. Cardiovascular protective effects of n-3 polyunsaturated fatty acids with special emphasis on docosahexaenoic acid. J Pharm Sci 2003; 92:308-316.
39. Cognault S, Jourdan ML, Germain E, et al. Effect of an α-linolenic acid-rich diet on rat mammary tumor growth depends on the dietary oxidative status. Nutr Cancer 2000;36:33-41.